In treating ovarian cancer, the targets for PF-0725787, the dual checkpoint inhibiting BsAb, were CD47/SIRPα and PD-1/PD-L1 in order to maximize anti-tumor immunity [146]. This evidence concerns the gene SIRPA and ovarian carcinoma.